Dublin, May 01, 2026 (GLOBE NEWSWIRE) — The “Cat Vaccine Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The global cat vaccine market has witnessed significant growth, expanding from $1.26 billion in 2025 to an expected $1.93 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.9%. This substantial growth aligns with increasing pet ownership, higher incidences of feline infectious diseases, and technological advancements in vaccine development. Moreover, rising awareness of preventive healthcare for pets and the expansion of veterinary and online services contribute significantly to this growth trajectory.
In recent years, the increasing prevalence of zoonotic diseases has become a pivotal driver for the cat vaccine market. These diseases, such as Lyme disease and toxoplasmosis, which can be transmitted from animals to humans, underscore the importance of vaccinations in reducing transmission risks. Vaccinating cats against these diseases helps mitigate their impact on human health, thereby supporting public health initiatives. Despite an uptick in zoonotic disease cases, demonstrated by the UK government’s report highlighting a rise in Lyme disease cases, the demand for cat vaccines continues to surge in response.
Market innovation is evidenced by key players like MSD Animal Health Inc., which launched the NOBIVAC NXT Rabies portfolio in June 2024. This product line employs advanced RNA-particle technology to enhance immune responses and vaccine efficacy without the need for adjuvants or preservatives, ensuring robust protection against rabies. In parallel, strategic acquisitions such as Boehringer Ingelheim Group’s purchase of Saiba Animal Health AG demonstrate an ongoing commitment to enhancing product portfolios and leveraging specialized expertise in feline vaccines.
The competitive landscape is rich with prominent players including Merck & Co., Boehringer Ingelheim, Zoetis, and Elanco Animal Health. North America currently leads the market, while Asia-Pacific is poised to experience the fastest growth. This regional expansion is supported by the increasing accessibility of veterinary healthcare and the integration of telemedicine and data analytics for enhanced disease monitoring.
Despite challenges such as tariffs impacting production costs of recombinant and DNA vaccines in North America and Europe, these barriers also fuel local manufacturing and innovation. The development of cost-effective vaccines and strengthened regional supply chains are expected outcomes, driving further advancement within the market.
The comprehensive cat vaccine market research report provides a deep dive into market statistics, including size, regional shares, and a competitive landscape overview. With detailed analyses of current and future market scenarios, this report equips stakeholders with the insights necessary to thrive in this dynamic industry.
Cats benefit from a broad spectrum of vaccines that address diseases like feline leukemia, panleukopenia, and rabies, with delivery methods ranging from injections to oral routes. The market encompasses modified live vaccines, inactivated, and recombinant technologies, catering through veterinary clinics, pet stores, and online platforms.
Report Scope:
- Vaccine Type: Modified or Attenuated Live; Inactivated; Other
- Disease Type: Feline Leukemia; Respiratory; Panleukopenia; Rabies; Others
- Technology: Conjugate; Inactivated; Subunit; Toxoid; DNA; Recombinant
- Administration: Injectable; Intranasal; Oral
- Distribution: Veterinary Clinics; Pet Stores; Online
- Countries and Regions: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain; Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
- Time Series: Five-year history and ten-year forecast
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026 – 2030 |
| Estimated Market Value (USD) in 2026 | $1.38 Billion |
| Forecasted Market Value (USD) by 2030 | $1.93 Billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
Major Trends
- Increased Adoption of Core Vaccination Programs
- Growth of Recombinant and Dna Vaccines
- Expansion of Veterinary Healthcare Services
- Rising Awareness of Pet Health and Disease Prevention
- Integration of Telemedicine and Remote Monitoring in Veterinary Care
Companies Featured
- Merck & Co. Inc.
- Boehringer Ingelheim International GmbH
- Zoetis Inc.
- MSD Animal Health
- Elanco Animal Health Incorporated
- Ceva Sante Animale
- Virbac
- HIPRA Corporation
- Bioveta AS
- Biogenesis Bago SA
- Torigen Pharmaceuticals Inc.
- Vetoquinol SA
- Phibro Animal Health Corporation
- IDT Biologika GmbH
- Vaxxinova BV
- Colorado Serum Company
- Huvepharma NV
- Bimeda Biologicals
- CAVAC
- Kyoto Biken Laboratories
- Avimex Animal Health
- Ringpu Biology
- Wuhan Keqian Biology
- Pulike Biological Engineering
- Chengdu Kanghua Biological Products
- Yebio
- FATRO
For more information about this report visit https://www.researchandmarkets.com/r/5ig33l
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
